AIM News and Press, AIM ImmunoTech Inc. From 04/11/22

What to Know About Trading Penny Stocks on April 11th With another week of trading penny stocks getting off to an interesting start, there is a lot for investors to know. Considering that there is still an extremely high amount of volatility in the stock market, investors need to be on ...

Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...

AIM ImmunoTech (NYSE:AIM) has added ~23% in the pre-market Monday after the clinical-stage biotech shared data for its cancer candidate Ampligen from trials targeted at metastatic triple-negative breast cancer and colorectal cancer. The ongoing Phase 2a trial for colorectal cancer m...

Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park Comprehensiv...

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term systemic CKM followed by pembrol...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

AIM ImmunoTech press release (NYSE:AIM): FY GAAP EPS of -$0.04. As of December 31, 2021, AIM reported cash and cash equivalents of $48.3 million, compared to $54.4 million as of December 31, 2020. For further details see: AIM ImmunoTech GAAP EPS of -$0.04

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen ® in multiple high-value indications - Company expected to continue advancing oncology-focused pipeline and well po...

OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...

Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...